AcceleRET-Lung

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 9, 2020 → Sep 11, 2026

Cited window

Feb 3, 2024 → Sep 11, 2026

Retrieved

Oct 28, 2026

Title

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Registry

NCT04222972

Study IDs

BO42864 · 2019-002463-10 · BLU-667-2303 (CT.Gov) · 2023-505035-12-00 (EU CT number)

Sponsor

Hoffmann-La Roche

Design

Phase 3 · Interventional, randomized, parallel

Status

Terminated

Enrollment

223 actual

Start

2020-07-24 actual

Primary completion

2025-01-27 actual

Primary endpoint

Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a remark on sponsor termination and accrual completeness when interpreting first-line pralsetinib evidence.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion. Repeated summaries and reposts cannot be counted as independent clinical agreement.
• –Discussion that did not clearly name the trial or used different spellings may be missing. Two passages were not fully assessed, so additional relevant views may be absent.
• –Only part of the available regulatory material was examined; the safety-alert relays are not a complete assessment of current labeling or all regulatory communications.
• –No primary publication of the randomized AcceleRET-Lung results is included. The reviewed publication concerns ARROW, a distinct single-arm phase I/II study.
• –Enrollment descriptions and termination timing differ across sources and have not been reconciled. Source-specific descriptions should not be silently standardized.
• –Post-amendment infection observations do not establish a causal reduction in mortality or prove that risk was eliminated; trial patients and the separate safety databases must remain distinct.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The sources do not provide a head-to-head ranking of selective RET inhibitors, specific toxicity differences for every alternative, or country-level European access criteria.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "AcceleRET-Lung" (NCT04222972), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "acceleret-lung-04222972". If you cannot make requests, read https://www.erudio.com/reports/acceleret-lung-nct04222972.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04222972", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04222972 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/acceleret-lung-nct04222972.json
curl https://www.erudio.com/reports/acceleret-lung-nct04222972.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "acceleret-lung-04222972" })